Hengjing Cui
Kuopio, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Novel PREP ligand, HUP-46, ameliorates behavioral deficits in an alpha-synuclein based Parkinson's disease model.
Journal: Experimental neurology
Published: September 12, 2025
5-Aminothiazoles Reveal a New Ligand-Binding Site on Prolyl Oligopeptidase Which is Important for Modulation of Its Protein-Protein Interaction-Derived Functions.
Journal: Journal of medicinal chemistry
Published: March 28, 2024
Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson's Disease.
Journal: Journal of medicinal chemistry
Published: May 29, 2023
A prolyl oligopeptidase inhibitor reduces tau pathology in cellular models and in mice with tauopathy.
Journal: Science translational medicine
Published: April 12, 2023
Nigrostriatal 6-hydroxydopamine lesions increase alpha-synuclein levels and permeability in rat colon.
Journal: Neurobiology of aging
Published: February 08, 2023
Deletion or inhibition of prolyl oligopeptidase blocks lithium-induced phosphorylation of GSK3b and Akt by activation of protein phosphatase 2A.
Journal: Basic & clinical pharmacology & toxicology
Published: May 03, 2021
Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy.
Journal: Journal of cellular and molecular medicine
Published: January 15, 2021
Corrigendum to "Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells" [Biomed. Pharmacother. 131 (2020) 110788].
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: November 28, 2020
Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: June 05, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026